Finn
BIIB Biotechnology · Large cap · Neurology · Rare disease · Thesis updated November 1, 2026

Top line growth accelerates as the new portfolio takes over

01 Running thesis

A turnaround with proof instead of promises

Biogen used to be mostly a multiple sclerosis drug company. That old base is still large, but it is shrinking as TECFIDERA faces generics and TYSABRI faces biosimilar competition. The key change is that the newer products are now big enough to matter. In Q3 2026, total revenue grew 11 percent year over year, and the growth portfolio reached $1.3 billion.

The bull case got stronger after Biogen successfully integrated Apellis. SYFOVRE and EMPAVELI combined for $243 million in Q3 2026. The company is capturing deal synergies faster than expected, which helps offset near-term earnings dilution. Biogen also filed a record five INDs in 2026, aiming to build an early-stage pipeline of more than 20 programs to sustain growth long after the current launches mature.

LEQEMBI also moved forward. The FDA approved LEQEMBI IQLIK for at-home starting and maintenance doses. That matters because the older IV version needs infusion center time, which can slow patient starts. Easier use does not guarantee fast adoption, but it attacks one of the biggest barriers.

The bear case is still real. Tighter Medicare Part D formulary management is actively pressuring growth products like VUMERITY, which saw sales drop 11 percent in Q3 2026. The company now has a better growth path, but it still has to prove that the new portfolio can outrun the old decline and navigate a tougher reimbursement environment.

Oct 2026▲Q3 2026 earnings marked a return to double-digit revenue growth. Total revenue rose 11 percent, the growth portfolio reached $1.3 billion, and SPINRAZA sales surged on high-dose adoption.
Jul 2026▲Q2 2026 results confirmed the growth pivot. The Apellis deal closed and contributed $128 million, LEQEMBI IQLIK was approved, and the growth portfolio passed $1 billion for the quarter.
Apr 2026▲Q1 2026 showed the pivot is no longer only a plan. Growth products reached $851 million and passed the remaining legacy MS products, while Biogen also announced the Apellis deal and high-dose SPINRAZA approvals.
Feb 2026▲The FDA accepted LEQEMBI IQLIK for weekly starting dose review, giving Biogen a clear Alzheimer's convenience catalyst. Biogen also made VUMERITY part of its growth product group.
Oct 2025→Q3 2025 revenue grew 3 percent year over year, helped by LEQEMBI, SKYCLARYS, and ZURZUVAE. The offset was lower full-year non-GAAP EPS guidance tied to planned business development spending.
Jul 2025▲Q2 2025 strengthened the turnaround case. Revenue grew 7 percent, non-GAAP EPS reached $5.25, and management raised full-year revenue and EPS guidance.
May 2025▲Q1 2025 gave early proof that new launches were offsetting the old MS decline. SKYCLARYS, LEQEMBI, and ZURZUVAE all showed traction, though EPS guidance moved lower because of deal costs.
02 Business model

Replacing MS cash with new launches

Biogen makes money by selling prescription drugs, earning collaboration revenue, and collecting royalties. The old engine is MS. TYSABRI, TECFIDERA, AVONEX, and PLEGRIDY still bring in large sales, but most of that group is under pressure from generic competition.

The new model is launch-heavy. Biogen is pushing LEQEMBI, SKYCLARYS, ZURZUVAE, QALSODY, high-dose SPINRAZA, and now Apellis medicines. This takes sales spending, doctor education, patient support, and payer coverage. Biogen is using its cost cuts to help fund that shift, while heavily investing in R&D to target complex therapeutic areas like immunology.

Where it breaks is simple. If LEQEMBI starts stay slow, SYFOVRE loses share, or Medicare Part D changes force heavy discounts on key drugs, the company could be stuck between a fading legacy business and an expensive growth plan.

03 Product portfolio

The drugs that decide the story

Cash cow

Legacy MS franchise

TECFIDERA, TYSABRI, AVONEX, and PLEGRIDY still matter, but the group is under pressure from generics, biosimilars, and patient shifts to newer options.

Growth engine

VUMERITY

Biogen counts VUMERITY as a growth product, though it faced an 11 percent revenue decline in Q3 2026 due to tighter Medicare Part D rules.

Growth engine

LEQEMBI

LEQEMBI is Biogen's Alzheimer's partnership with Eisai. The approval of LEQEMBI IQLIK for at-home doses could make treatment easier for doctors and patients.

Steady

SPINRAZA

SPINRAZA treats spinal muscular atrophy. The high-dose regimen is driving a major revenue resurgence and helping Biogen defend against oral rivals.

Growth engine

SKYCLARYS, QALSODY, and ZURZUVAE

These newer launches cover Friedreich's ataxia, SOD1-ALS, and postpartum depression. In Q3 2026, SKYCLARYS generated $178 million.

Growth engine

SYFOVRE and EMPAVELI

Biogen gained these drugs through Apellis. They generated $243 million in Q3 2026, providing immediate top-line growth.

Option

Late-stage pipeline

Key pipeline bets include litifilimab for lupus, and felzartamab for kidney disease and microvascular inflammation.

04 Business segments

Revenue mix transition

Product revenue71%modest
Anti-CD20 therapeutic programs17%modest
Alzheimer's collaboration revenue2%growing fast
Contract manufacturing, royalty and other revenue10%declining

The mix reflects Biogen's broad revenue categories. Product revenue includes MS, rare disease, biosimilars, and the newly added Apellis medicines.

05 Risk factors

What could still go wrong

Apellis integration and SYFOVRE pressure

High impact · Medium odds

Biogen paid about $5.6 billion for Apellis, adding debt and near-term dilution. SYFOVRE sells into geographic atrophy, a highly competitive market. If Biogen cannot stabilize or grow SYFOVRE, the deal may add debt without enough earnings power.

We watchSYFOVRE quarterly sales, geographic atrophy market share, and Apellis-related earnings impacts.

LEQEMBI adoption stays slow

High impact · Medium odds

LEQEMBI has a huge possible market, but uptake has been slowed by health system limits. At-home LEQEMBI IQLIK helps with convenience, but patients still need screening and coverage. If doctors and payers move slowly, Alzheimer's revenue may not ramp fast enough.

We watchNew patient starts, payer coverage for LEQEMBI IQLIK, and management comments on Alzheimer's treatment capacity.

Legacy MS decline outruns launches

High impact · High odds

Biogen's MS base is still large but fading. TECFIDERA and TYSABRI face generic and biosimilar competition. The company paused its own new MS drug because of market crowding.

We watchQuarterly TECFIDERA, TYSABRI, and total MS revenue trends.

Drug pricing and policy pressure

Medium impact · High odds

The Medicare Part D redesign and tighter formulary management are actively suppressing revenues for products like VUMERITY. More pricing pressure or Medicare changes could weigh heavily on sales and margins.

We watchMedicare Part D impact, U.S. drug pricing rules, and VUMERITY sales performance.
06 Quick answers

In one breath

What is Biogen best known for?

Biogen is best known for neurology drugs, especially MS treatments and SPINRAZA for spinal muscular atrophy. It is now trying to become a broader company built around Alzheimer's, rare disease, immunology, and eye disease drugs.

Why did Biogen buy Apellis?

Biogen bought Apellis to add two marketed drugs right away: SYFOVRE and EMPAVELI. The deal is meant to make revenue growth less dependent on slow pipeline progress.

Why does LEQEMBI IQLIK matter?

LEQEMBI IQLIK lets patients receive Alzheimer's treatment with at-home injections instead of starting with IV infusions. That could lower the burden on patients, doctors, and infusion centers.

Is Biogen already growing again?

Yes. In Q3 2026, total revenue grew 11 percent year over year to $2.8 billion, driven by a $1.3 billion contribution from the growth products segment.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 1, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Biogen Q3 2026 earnings transcript
  2. Biogen Q2 2026 Form 10-Q
08 Explore the industry

Comparable Drug Manufacturers - General companies

Companies near Biogen Inc. in Finn's Drug Manufacturers - General industry ranking.

Get started with Finn today